Shopping Cart
Remove All
Your shopping cart is currently empty
Teprotumumab (Synonyms: R 1507, HZN 001)
Catalog No. T76727 Copy Product Info
🥰Excellent
Teprotumumab is a human monoclonal antibody that blocks the IGF-1 receptor (IGF-1R). Teprotumumab binds to the extracellular α-subunit domain ligand of IGF-1R. Teprotumumab inhibits TSH and IGF-1 action in fibrocytes. Teprotumumab reduces TSH-dependent IL-6 and IL-8 expression and Akt phosphorylation. Teprotumumab can be used in the study of thyroid-associated eye diseases.
Teprotumumab
Copy Product Info🥰Excellent
Catalog No. T76727
Synonyms R 1507, HZN 001
Teprotumumab is a human monoclonal antibody that blocks the IGF-1 receptor (IGF-1R). Teprotumumab binds to the extracellular α-subunit domain ligand of IGF-1R. Teprotumumab inhibits TSH and IGF-1 action in fibrocytes. Teprotumumab reduces TSH-dependent IL-6 and IL-8 expression and Akt phosphorylation. Teprotumumab can be used in the study of thyroid-associated eye diseases.
Teprotumumab
Cas No. 1036734-93-6
Customer service consultation
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | $163 | - | In Stock | |
| 5 mg | $463 | In Stock | In Stock | |
| 10 mg | $742 | In Stock | In Stock | |
| 25 mg | $1,120 | Inquiry | Inquiry | |
| 50 mg | $1,490 | Inquiry | Inquiry |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
For research use only—not for human use. No sales to individuals. Use as intended only.
Batch Information
Select Batch
Purity:95.2% (SDS-PAGE); 99.6% (SEC-HPLC)
Appearance:Liquid
Color:Transparent
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Teprotumumab is a human monoclonal antibody that blocks the IGF-1 receptor (IGF-1R). Teprotumumab binds to the extracellular α-subunit domain ligand of IGF-1R. Teprotumumab inhibits TSH and IGF-1 action in fibrocytes. Teprotumumab reduces TSH-dependent IL-6 and IL-8 expression and Akt phosphorylation. Teprotumumab can be used in the study of thyroid-associated eye diseases. |
| In vitro | In fibrocytes, Teprotumumab (0-500 μg/mL, 12 h) attenuates the actions of both IGF-1 and TSH. However, the mRNA abundance of IGF-1R and TSHR is unaffected by Teprotumumab after 24 hours[1]. |
| Synonyms | R 1507, HZN 001 |
| Reactivity | Human |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Gene ID | |
| Uniprot ID | |
| Target | IGF1-R/IGFR1/CD221 |
| Molecular Weight | 145.62 kDa |
| Cas No. | 1036734-93-6 |
| Isotype | Human IgG1 kappa |
| Recommended Isotype Control |
| Storage | Store at low temperature | Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Preview
Related Tags: buy Teprotumumab | purchase Teprotumumab | Teprotumumab cost | order Teprotumumab | Teprotumumab in vitro | Teprotumumab molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.